Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

Español • Italiano • Sardu • English | PDF+


  Prostate Cancer

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 82 articles:
HTML format
Text format



Single Articles


    July 2019

  1. Retraction: Festuccia, C., Gravina, G. L., Angelucci, A., Millimaggi, D., Muzi, P., Vicentini, C. and Bologna, M. (2005), Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonster
    Int J Cancer. 2019;145:E12.
    PubMed     Text format     Abstract available


    May 2019
  2. MITRAN B, Rinne SS, Konijnenberg MW, Maina T, et al
    Trastuzumab co-treatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist (177) Lu-DOTAGA-PEG2 -RM26.
    Int J Cancer. 2019 May 11. doi: 10.1002/ijc.32401.
    PubMed     Text format     Abstract available


    April 2019
  3. WANG R, Chu GC, Wang X, Wu JB, et al
    Establishment and characterization of a prostate cancer cell line from a prostatectomy specimen for the study of cellular interaction.
    Int J Cancer. 2019 Apr 24. doi: 10.1002/ijc.32370.
    PubMed     Text format     Abstract available


  4. GORODETSKA I, Lukiyanchuk V, Peitzsch C, Kozeretska I, et al
    BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
    Int J Cancer. 2019 Apr 10. doi: 10.1002/ijc.32323.
    PubMed     Text format     Abstract available


  5. SCHMIDT JA, Fensom GK, Rinaldi S, Scalbert A, et al
    Patterns in metabolite profile are associated with risk of more aggressive prostate cancer: a prospective study of 3057 matched case-control sets from EPIC.
    Int J Cancer. 2019 Apr 5. doi: 10.1002/ijc.32314.
    PubMed     Text format     Abstract available


    March 2019
  6. FREDSOE J, Rasmussen AKI, Mouritzen P, Borre M, et al
    A five-microRNA model (pCaP) for predicting prostate cancer aggressiveness using cell-free urine.
    Int J Cancer. 2019 Mar 23. doi: 10.1002/ijc.32296.
    PubMed     Text format     Abstract available


  7. BRUREAU L, Emeville E, Helissey C, Thome JP, et al
    Endocrine Disrupting-Chemicals and Biochemical Recurrence of Prostate Cancer after Prostatectomy: A cohort study in Guadeloupe (French West Indies).
    Int J Cancer. 2019 Mar 20. doi: 10.1002/ijc.32287.
    PubMed     Text format     Abstract available


  8. SUGAWARA T, Baumgart SJ, Nevedomskaya E, Reichert K, et al
    Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models.
    Int J Cancer. 2019 Mar 3. doi: 10.1002/ijc.32242.
    PubMed     Text format     Abstract available


    February 2019
  9. PEREZ-CORNAGO A, Huybrechts I, Appleby PN, Schmidt JA, et al
    Intake of Individual Fatty Acids and Risk of Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition.
    Int J Cancer. 2019 Feb 26. doi: 10.1002/ijc.32233.
    PubMed     Text format     Abstract available


  10. MARIN-AGUILERA M, Reig O, Mila-Guasch M, Font A, et al
    The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.
    Int J Cancer. 2019 Feb 26. doi: 10.1002/ijc.32238.
    PubMed     Text format     Abstract available


  11. HUANG J, Mondul AM, Weinstein SJ, Derkach A, et al
    Prospective Serum Metabolomic Profiling of Lethal Prostate Cancer.
    Int J Cancer. 2019 Feb 18. doi: 10.1002/ijc.32218.
    PubMed     Text format     Abstract available


    January 2019
  12. WENDEU-FOYET MG, Koudou Y, Cenee S, Tretarre B, et al
    Circadian genes and risk of prostate cancer: findings from the EPICAP study.
    Int J Cancer. 2019 Jan 21. doi: 10.1002/ijc.32149.
    PubMed     Text format     Abstract available


  13. LINDBERG A, Talala K, Kujala P, Stenman UH, et al
    Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish Randomized Study of Screening for Prostate Cancer.
    Int J Cancer. 2019 Jan 17. doi: 10.1002/ijc.32129.
    PubMed     Text format     Abstract available


  14. LIU Q, Wang G, Li Q, Jiang W, et al
    Polycomb Group Proteins EZH2 and EED Directly Regulate Androgen Receptor in Advanced Prostate Cancer.
    Int J Cancer. 2019 Jan 10. doi: 10.1002/ijc.32118.
    PubMed     Text format     Abstract available


    December 2018
  15. GAO X, Wilsgaard T, Jansen EH, Holleczek B, et al
    Pre-diagnostic derivatives of reactive oxygen metabolites and the occurrence of lung, colorectal, breast and prostate cancer: An individual participant data meta-analysis of two large population-based studies.
    Int J Cancer. 2018 Dec 18. doi: 10.1002/ijc.32073.
    PubMed     Text format     Abstract available


  16. PARRY MG, Sujenthiran A, Cowling TE, Nossiter J, et al
    Impact of cancer service centralisation on the radical treatment of men with high-risk and locally advanced prostate cancer: A national cross-sectional analysis in England.
    Int J Cancer. 2018 Dec 14. doi: 10.1002/ijc.32068.
    PubMed     Text format     Abstract available


  17. MO RJ, Han ZD, Liang YK, Ye JH, et al
    Expression of PD-L1 in tumor-associated nerves correlates with reduced CD8(+) tumor-associated lymphocytes and poor prognosis in prostate cancer.
    Int J Cancer. 2018 Dec 11. doi: 10.1002/ijc.32061.
    PubMed     Text format     Abstract available


  18. GRAF ME, Sookthai D, Johnson T, Schubel R, et al
    Pre-diagnostic plasma concentrations of Fibrinogen, sGPIIb/IIIa, sP-selectin, sThrombomodulin, Thrombopoietin in relation to cancer risk: Findings from a large prospective study.
    Int J Cancer. 2018;143:2659-2667.
    PubMed     Text format     Abstract available


    November 2018
  19. KOCHER S, Beyer B, Lange T, Nordquist L, et al
    A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer.
    Int J Cancer. 2018 Nov 26. doi: 10.1002/ijc.32018.
    PubMed     Text format     Abstract available


  20. SROUR B, Plancoulaine S, Andreeva VA, Fassier P, et al
    Circadian nutritional behaviours and cancer risk: New insights from the NutriNet-sante prospective cohort study: Disclaimers.
    Int J Cancer. 2018;143:2369-2379.
    PubMed     Text format     Abstract available


  21. YUAN C, Shui IM, Wilson KM, Stampfer MJ, et al
    Circulating 25-hydroxyvitamin D, vitamin D binding protein, and risk of advanced and lethal prostate cancer.
    Int J Cancer. 2018 Nov 9. doi: 10.1002/ijc.31966.
    PubMed     Text format     Abstract available


    October 2018
  22. BEYNON R, Richmond RC, Santos Ferreira DL, Ness AR, et al
    Investigating the effects of lycopene and green tea on the metabolome of men at risk of prostate cancer: The ProDiet randomised controlled trial.
    Int J Cancer. 2018 Oct 16. doi: 10.1002/ijc.31929.
    PubMed     Text format     Abstract available


  23. ZHANG AY, Chiam K, Haupt Y, Fox S, et al
    An Analysis of a Multiple Biomarker Panel to Better Predict Prostate Cancer Metastasis After Radical Prostatectomy.
    Int J Cancer. 2018 Oct 4. doi: 10.1002/ijc.31906.
    PubMed     Text format     Abstract available


    September 2018
  24. OMARI A, Nastaly P, Stoupiec S, Balabas A, et al
    Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR and tumor progression in prostate cancer.
    Int J Cancer. 2018 Sep 28. doi: 10.1002/ijc.31905.
    PubMed     Text format     Abstract available


  25. JI J, Sundquist J, Sundquist K
    Use of terbinafine and risk of death in patients with prostate cancer: A population-based cohort study.
    Int J Cancer. 2018 Sep 27. doi: 10.1002/ijc.31901.
    PubMed     Text format     Abstract available


  26. KRISTENSEN KB, Jensen PH, Skriver C, Friis S, et al
    Use of vitamin K antagonists and risk of prostate cancer: Meta-analysis and nationwide case-control study.
    Int J Cancer. 2018 Sep 24. doi: 10.1002/ijc.31886.
    PubMed     Text format     Abstract available


  27. TSANG SH, Peisch SF, Rowan B, Markt SC, et al
    Association between Trichomonas vaginalis and prostate cancer mortality.
    Int J Cancer. 2018 Sep 22. doi: 10.1002/ijc.31885.
    PubMed     Text format     Abstract available


  28. HU B, Hu H, Yin M, Sun Z, et al
    Sertad1 promotes prostate cancer progression through binding androgen receptor ligand binding domain.
    Int J Cancer. 2018 Sep 19. doi: 10.1002/ijc.31877.
    PubMed     Text format     Abstract available


  29. BRADBURY KE, Appleby PN, Tipper SJ, Travis RC, et al
    Circulating insulin-like growth factor I in relation to melanoma risk in the European Prospective Investigation into Cancer and Nutrition.
    Int J Cancer. 2018 Sep 7. doi: 10.1002/ijc.31854.
    PubMed     Text format     Abstract available


  30. LEE KH, Hong S, Kang M, Jeong CW, et al
    Histone demethylase KDM7A controls androgen receptor activity and tumor growth in prostate cancer.
    Int J Cancer. 2018 Sep 5. doi: 10.1002/ijc.31843.
    PubMed     Text format     Abstract available


    August 2018
  31. KAIKKONEN E, Rantapero T, Zhang Q, Taimen P, et al
    ANO7 is associated with aggressive prostate cancer.
    Int J Cancer. 2018 Aug 29. doi: 10.1002/ijc.31746.
    PubMed     Text format     Abstract available


  32. MASSILLO C, Dalton GN, Porretti J, Scalise GD, et al
    CTBP1/CYP19A1/Estradiol axis together with adipose tissue impacts over prostate cancer growth associated to metabolic syndrome.
    Int J Cancer. 2018 Aug 28. doi: 10.1002/ijc.31773.
    PubMed     Text format     Abstract available


  33. LAKSHMANA G, Baniahmad A
    Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
    Int J Cancer. 2018 Aug 19. doi: 10.1002/ijc.31818.
    PubMed     Text format     Abstract available


  34. SANTALA EE, Rannikko A, Murtola TJ
    Antihypertensive drugs and prostate cancer survival after radical prostatectomy in Finland - a nationwide cohort study.
    Int J Cancer. 2018 Aug 15. doi: 10.1002/ijc.31802.
    PubMed     Text format     Abstract available


  35. BAO C, Pedersen NL, Yang R, Marseglia A, et al
    Diabetes in midlife and risk of cancer in late life: A nationwide Swedish twin study.
    Int J Cancer. 2018;143:793-800.
    PubMed     Text format     Abstract available


  36. COLLINS RJ, Morgan LD, Owen S, Ruge F, et al
    Mechanistic insights of Epithelial Protein Lost in Neoplasm in prostate cancer metastasis.
    Int J Cancer. 2018 Aug 11. doi: 10.1002/ijc.31786.
    PubMed     Text format     Abstract available


    July 2018
  37. KOGEVINAS M, Espinosa A, Castello A, Gomez-Acebo I, et al
    Effect of mistimed eating patterns on breast and prostate cancer risk (MCC-Spain Study).
    Int J Cancer. 2018 Jul 17. doi: 10.1002/ijc.31649.
    PubMed     Text format     Abstract available


  38. SAMPSON N, Brunner E, Weber A, Puhr M, et al
    Inhibition of Nox4-dependent ROS signaling attenuates prostate fibroblast activation and abrogates stromal-mediated protumorigenic interactions.
    Int J Cancer. 2018;143:383-395.
    PubMed     Text format     Abstract available


  39. ANDREE KC, Mentink A, Zeune LL, Terstappen LWMM, et al
    Towards a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multi-center study (CTCTrap).
    Int J Cancer. 2018 Jul 14. doi: 10.1002/ijc.31752.
    PubMed     Text format     Abstract available


  40. PEREZ-CORNAGO A, Appleby PN, Boeing H, Gil L, et al
    Circulating isoflavone and lignan concentrations and prostate cancer risk: A meta-analysis of individual participant data from seven prospective studies including 2828 cases and 5593 controls.
    Int J Cancer. 2018 Jul 4. doi: 10.1002/ijc.31640.
    PubMed     Text format     Abstract available


    June 2018
  41. SEN A, Papadimitriou N, Lagiou P, Perez-Cornago A, et al
    Coffee and tea consumption and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition.
    Int J Cancer. 2018 Jun 26. doi: 10.1002/ijc.31634.
    PubMed     Text format     Abstract available


    May 2018
  42. HAGGSTROM C, Van Hemelrijck M, Garmo H, Robinson D, et al
    Heterogeneity in risk of prostate cancer: A Swedish population-based cohort study of competing risks and type 2 diabetes mellitus.
    Int J Cancer. 2018 May 9. doi: 10.1002/ijc.31587.
    PubMed     Text format     Abstract available


    April 2018
  43. OKI R, Ito K, Suzuki R, Fujizuka Y, et al
    Long-term longitudinal changes in baseline PSA distribution and estimated prevalence of prostate cancer in male Japanese participants of population-based PSA screening.
    Int J Cancer. 2018 Apr 26. doi: 10.1002/ijc.31560.
    PubMed     Text format     Abstract available


  44. URBIOLA C, Santer FR, Petersson M, van der Pluijm G, et al
    Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer.
    Int J Cancer. 2018 Apr 26. doi: 10.1002/ijc.31556.
    PubMed     Text format     Abstract available


  45. DOAT S, Marous M, Rebillard X, Tretarre B, et al
    Prostatitis, other genitourinary infections and prostate cancer risk: Influence of non-steroidal anti-inflammatory drugs? Results from the EPICAP study.
    Int J Cancer. 2018 Apr 26. doi: 10.1002/ijc.31565.
    PubMed     Text format     Abstract available


    March 2018
  46. BELIC J, Graf R, Bauernhofer T, Cherkas Y, et al
    Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.
    Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31397.
    PubMed     Text format     Abstract available


  47. PORRETTI J, Dalton GN, Massillo C, Scalise GD, et al
    CLCA2 epigenetic regulation by CTBP1, HDACs, ZEB1, EP300 and miR-196b-5p impacts prostate cancer cell adhesion and EMT in metabolic syndrome disease.
    Int J Cancer. 2018 Mar 14. doi: 10.1002/ijc.31379.
    PubMed     Text format     Abstract available


    February 2018
  48. CUI J, Wang Y, Dong B, Qin L, et al
    Pharmacological Inhibition of the Notch Pathway Enhances the Efficacy of Androgen Deprivation Therapy for Prostate Cancer.
    Int J Cancer. 2018 Feb 27. doi: 10.1002/ijc.31346.
    PubMed     Text format     Abstract available


  49. QU S, Xue H, Dong X, Lin D, et al
    Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model.
    Int J Cancer. 2018 Feb 14. doi: 10.1002/ijc.31310.
    PubMed     Text format     Abstract available


  50. SHAO Y, Ye G, Ren S, Piao HL, et al
    Metabolomics and transcriptomics profiles reveal the dysregulation of the tricarboxylic acid cycle and related mechanisms in prostate cancer.
    Int J Cancer. 2018 Feb 14. doi: 10.1002/ijc.31313.
    PubMed     Text format     Abstract available


  51. FARRIS MS, Courneya KS, Kopciuk KA, McGregor SE, et al
    Post-diagnosis alcohol intake and prostate cancer survival: A population-based cohort study.
    Int J Cancer. 2018 Feb 13. doi: 10.1002/ijc.31307.
    PubMed     Text format     Abstract available


  52. DAWE DE, Ye X, Czaykowski P, Jassal D, et al
    The effect of statin use on the incidence of prostate cancer: A population-based nested case-control study.
    Int J Cancer. 2018 Feb 6. doi: 10.1002/ijc.31295.
    PubMed     Text format     Abstract available


    January 2018
  53. TOMIC K, Ventimiglia E, Robinson D, Haggstrom C, et al
    Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study.
    Int J Cancer. 2018 Jan 24. doi: 10.1002/ijc.31272.
    PubMed     Text format     Abstract available


  54. ARTHUR R, Williams R, Garmo H, Holmberg L, et al
    Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study.
    Int J Cancer. 2018 Jan 11. doi: 10.1002/ijc.31256.
    PubMed     Text format     Abstract available


  55. WU J, Wilson KM, Stampfer MJ, Willett WC, et al
    A 24-year prospective study of dietary alpha-linolenic acid and lethal prostate cancer.
    Int J Cancer. 2018 Jan 8. doi: 10.1002/ijc.31247.
    PubMed     Text format     Abstract available


    December 2017
  56. LUO Y, Azad AK, Karanika S, Basourakos SP, et al
    Enzalutamide and CXCR7 inhibitor Combination Treatment Suppresses Cell Growth and Angiogenic Signaling in Castration-Resistant Prostate Cancer Models.
    Int J Cancer. 2017 Dec 26. doi: 10.1002/ijc.31237.
    PubMed     Text format     Abstract available


  57. KHAN S, Hicks V, Colditz GA, Kibel AS, et al
    The association of weight change in young adulthood and smoking status with risk of prostate cancer recurrence.
    Int J Cancer. 2017 Dec 22. doi: 10.1002/ijc.31229.
    PubMed     Text format     Abstract available


  58. RIDGE SM, Bhattacharyya D, Dervan E, Naicker SD, et al
    Secreted Factors from Metastatic Prostate Cancer Cells Stimulate Mesenchymal Stem Cell Transition to a Pro-tumourigenic 'Activated' State that Enhances Prostate Cancer Cell Migration.
    Int J Cancer. 2017 Dec 20. doi: 10.1002/ijc.31226.
    PubMed     Text format     Abstract available


  59. UGGE H, Udumyan R, Carlsson J, Andren O, et al
    Acne in late adolescence and risk of prostate cancer.
    Int J Cancer. 2017 Dec 4. doi: 10.1002/ijc.31192.
    PubMed     Text format     Abstract available


    November 2017
  60. GONZALEZ-MENENDEZ P, Hevia D, Mayo JC, Sainz RM, et al
    The dark side of glucose transporters in prostate cancer: Are they a new feature to characterize carcinomas?
    Int J Cancer. 2017 Nov 21. doi: 10.1002/ijc.31165.
    PubMed     Text format     Abstract available


  61. REGER MK, Zollinger TW, Liu Z, Jones JF, et al
    Dietary intake of isoflavones and coumestrol and the risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2017 Nov 8. doi: 10.1002/ijc.31095.
    PubMed     Text format     Abstract available


  62. BARRDAHL M, Canzian F, Gaudet MM, Gapstur SM, et al
    A comprehensive analysis of polymorphic variants in steroid hormone and IGF-1 metabolism and risk of in situ breast cancer: results from the Breast and Prostate Cancer Cohort (BPC3) Consortium.
    Int J Cancer. 2017 Nov 7. doi: 10.1002/ijc.31145.
    PubMed     Text format     Abstract available


  63. DICKERMAN BA, Torfadottir JE, Valdimarsdottir UA, Wilson KM, et al
    Midlife metabolic factors and prostate cancer risk in later life.
    Int J Cancer. 2017 Nov 7. doi: 10.1002/ijc.31142.
    PubMed     Text format     Abstract available


    October 2017
  64. SEIKKULA HA, Kaipia AJ, Ryynanen H, Seppa K, et al
    The impact of socioeconomic status on stage specific prostate cancer survival and mortality before and after introduction of PSA test in Finland.
    Int J Cancer. 2017 Oct 16. doi: 10.1002/ijc.31109.
    PubMed     Text format     Abstract available


  65. HEIJNSDIJK EAM, Bangma CH, Borras JM, de Carvalho TM, et al
    Summary statement on screening for prostate cancer in Europe.
    Int J Cancer. 2017 Oct 12. doi: 10.1002/ijc.31102.
    PubMed     Text format     Abstract available



  66. Retraction: 'Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells' by Nobuyuki Kikuno, Hiroaki Shiina, Shinji Urakami, Ken Kawamoto, Hiroshi Hirata, Yuichiro Tanaka, Shahana Majid, Mikio Ig
    Int J Cancer. 2017;141:1492.
    PubMed     Text format     Abstract available


    August 2017
  67. CHASIMPHA SJD, Parkin DM, Masamba L, Dzamalala CP, et al
    Three-year cancer incidence in Blantyre, Malawi (2008-2010).
    Int J Cancer. 2017;141:694-700.
    PubMed     Text format     Abstract available


  68. KVALE R, Myklebust TA, Engholm G, Heinavaara S, et al
    Prostate and breast cancer in four Nordic countries: A comparison of incidence and mortality trends across countries and age groups 1975-2013.
    Int J Cancer. 2017 Aug 10. doi: 10.1002/ijc.30924.
    PubMed     Text format     Abstract available


    July 2017
  69. LIN HM, Mahon KL, Weir JM, Mundra PA, et al
    A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer: Authors.
    Int J Cancer. 2017 Jul 25. doi: 10.1002/ijc.30903.
    PubMed     Text format     Abstract available


  70. WANG B, Lo UG, Wu K, Kapur P, et al
    Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer.
    Int J Cancer. 2017 Jul 19. doi: 10.1002/ijc.30893.
    PubMed     Text format     Abstract available


  71. WANG K, Chen X, Bird VY, Gerke TA, et al
    Association between Age-Related Reductions in Testosterone and Risk of Prostate Cancer - An Analysis of Patients' Data with Prostatic Diseases.
    Int J Cancer. 2017 Jul 12. doi: 10.1002/ijc.30882.
    PubMed     Text format     Abstract available


  72. GU F, Zhang H, Hyland PL, Berndt S, et al
    Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia.
    Int J Cancer. 2017 Jul 12. doi: 10.1002/ijc.30883.
    PubMed     Text format     Abstract available


  73. SCHECHER S, Walter B, Falkenstein M, Macher-Goeppinger S, et al
    Cyclin K dependent regulation of Aurora B affects apoptosis and proliferation by induction of mitotic catastrophe in prostate cancer.
    Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30864.
    PubMed     Text format     Abstract available


    June 2017
  74. AL-QATATI A, Akrong C, Stevic I, Pantel K, et al
    Plasma microRNA signature is associated with risk stratification in prostate cancer patients.
    Int J Cancer. 2017 Jun 1. doi: 10.1002/ijc.30815.
    PubMed     Text format     Abstract available


    May 2017
  75. DICKERMAN BA, Ahearn TU, Giovannucci E, Stampfer MJ, et al
    Weight change, obesity, and risk of prostate cancer progression among men with clinically localized prostate cancer.
    Int J Cancer. 2017 May 23. doi: 10.1002/ijc.30803.
    PubMed     Text format     Abstract available


  76. WANG Y, Freedman JA, Liu H, Moorman PG, et al
    Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer.
    Int J Cancer. 2017 May 16. doi: 10.1002/ijc.30787.
    PubMed     Text format     Abstract available


    April 2017
  77. POUNIS G, Tabolacci C, Costanzo S, Cordella M, et al
    Reduction by coffee consumption of prostate cancer risk: Evidence from the Moli-sani cohort and cellular models.
    Int J Cancer. 2017 Apr 24. doi: 10.1002/ijc.30720.
    PubMed     Text format     Abstract available


  78. PEREZ-CORNAGO A, Travis RC, Appleby PN, Tsilidis KK, et al
    Fruit and vegetable intake and prostate cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC).
    Int J Cancer. 2017 Apr 17. doi: 10.1002/ijc.30741.
    PubMed     Text format     Abstract available


  79. ROMAGUERA D, Gracia-Lavedan E, Molinuevo A, de Batlle J, et al
    Adherence to nutrition-based cancer prevention guidelines and breast, prostate and colorectal cancer risk in the MCC-Spain case-control study.
    Int J Cancer. 2017 Apr 5. doi: 10.1002/ijc.30722.
    PubMed     Text format     Abstract available


    March 2017
  80. KAWADA T
    Dairy intake and prostate cancer survival.
    Int J Cancer. 2017 Mar 23. doi: 10.1002/ijc.30703.
    PubMed     Text format    


    January 2017
  81. LUBIK AA, Nouri M, Truong S, Ghaffari M, et al
    Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment.
    Int J Cancer. 2017;140:358-369.
    PubMed     Text format     Abstract available


    October 2016
  82. TRABERT B, Eldridge RC, Pfeiffer RM, Shiels MS, et al
    Pre-diagnostic circulating inflammation markers and endometrial cancer risk in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.
    Int J Cancer. 2016 Oct 22. doi: 10.1002/ijc.30478.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: